Presentation is loading. Please wait.

Presentation is loading. Please wait.

Opening Up to Precompetitive Collaboration

Published byKevin Fox Modified over 4 years ago

Similar presentations

Presentation on theme: "Opening Up to Precompetitive Collaboration"— Presentation transcript:

1 Opening Up to Precompetitive Collaboration
by Jill S. Altshuler, Erin Balogh, Anna D. Barker, Stephen L. Eck, Stephen H. Friend, Geoffrey S. Ginsburg, Roy S. Herbst, Sharyl J. Nass, Christopher M. Streeter, and John A. Wagner Sci Transl Med Volume 2(52):52cm26-52cm26 October 6, 2010 Copyright © 2010, American Association for the Advancement of Science

2 Fig. 1. Precompetitive participants
Fig. 1. Precompetitive participants. Collaborations and consortia can be open or restricted both in terms of those who directly contribute (for example, scientifically) (Contributors) versus those who will directly access the outputs (Output access), suggesting four potential combinations: restricted/open (blue); restricted/restricte Collaborations and consortia can be open or restricted both in terms of those who directly contribute (for example, scientifically) (Contributors) versus those who will directly access the outputs (Output access), suggesting four potential combinations: restricted/open (blue); restricted/restricted (tan); open/open (green); and open/restricted (salmon). Jill S. Altshuler et al., Sci Transl Med 2010;2:52cm26 Copyright © 2010, American Association for the Advancement of Science

3 Fig. 2. Mapping precompetitive collaborations
Fig. 2. Mapping precompetitive collaborations. In mapping goals versus participants, eight models of precompetitive collaboration emerged (please see text for details). In mapping goals versus participants, eight models of precompetitive collaboration emerged (please see text for details). The four broad goals listed across the top of the figure encompass all steps along the R&D value chain. The color-coding of the types of collaborations (open or restricted contributors and output access) defined in Fig. 1 is used here at the left. Open Health NLP, Open Health Natural Language Processing; GSK, GlaxoSmithKline; P&G, Procter and Gamble. Jill S. Altshuler et al., Sci Transl Med 2010;2:52cm26 Copyright © 2010, American Association for the Advancement of Science

Download ppt "Opening Up to Precompetitive Collaboration"

Similar presentations

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 1. Map showing the study catchment area in the East of England.
Examples of AEGIS autonomous target selection.

Examples of AEGIS autonomous target selection.
Fig. 1 A single amino acid difference in the ATP-binding domain of GSK3α and GSK3β results in structural and topological differences. A single amino acid.

Fig. 1 A single amino acid difference in the ATP-binding domain of GSK3α and GSK3β results in structural and topological differences. A single amino acid.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Fig. 1 Movement percepts for all participants.

Fig. 1 Movement percepts for all participants.
Fig. 1 Biomass over time of C3 grasses and C4 grasses at ambient and elevated CO2. Biomass over time of C3 grasses and C4 grasses at ambient and elevated.

Fig. 1 Biomass over time of C3 grasses and C4 grasses at ambient and elevated CO2. Biomass over time of C3 grasses and C4 grasses at ambient and elevated.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 3. Comparison of prediction performance.

Fig. 3. Comparison of prediction performance.
Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.
Fig. 1. Animal instincts. Animal instincts. Half-horse, half-human, the mythological centaur Chiron (root, chirourgos: surgeon) taught all of the great.

Fig. 1. Animal instincts. Animal instincts. Half-horse, half-human, the mythological centaur Chiron (root, chirourgos: surgeon) taught all of the great.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.
Fig. 1 Map of water stress and shale plays.

Fig. 1 Map of water stress and shale plays.
In vivo release of doxycycline hyclate from the GRS in a swine model

In vivo release of doxycycline hyclate from the GRS in a swine model
Fig. 2 Some examples of weekly forecasts (the number of the forecasts are reported on Table 1). Some examples of weekly forecasts (the number of the forecasts.

Fig. 2 Some examples of weekly forecasts (the number of the forecasts are reported on Table 1). Some examples of weekly forecasts (the number of the forecasts.
Fig. 1. Value proposition. Value proposition.Summarized are the valuation estimates (log scale), from panel members (selected by A.W.L.) for the NCATS.

Fig. 1. Value proposition. Value proposition.Summarized are the valuation estimates (log scale), from panel members (selected by A.W.L.) for the NCATS.
Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Similar presentations

Ads by Google